HDAC4 in Cancer: A Multitasking Platform to Drive Not Only Epigenetic Modifications

Overview

Journal Front Mol Biosci

Specialty Biology

Date 2023 Feb 10

PMID 36762207

Authors

Emma Cuttini

Camilla Goi

Ester Pellarin

Riccardo Vida

Claudio Brancolini

Affiliations

Soon will be listed here.

Abstract

Controlling access to genomic information and maintaining its stability are key aspects of cell life. Histone acetylation is a reversible epigenetic modification that allows access to DNA and the assembly of protein complexes that regulate mainly transcription but also other activities. Enzymes known as histone deacetylases (HDACs) are involved in the removal of the acetyl-group or in some cases of small hydrophobic moieties from histones but also from the non-histone substrate. The main achievement of HDACs on histones is to repress transcription and promote the formation of more compact chromatin. There are 18 different HDACs encoded in the human genome. Here we will discuss HDAC4, a member of the class IIa family, and its possible contribution to cancer development.

Citing Articles

Prostate Cancer: De-regulated Circular RNAs With Efficacy in Preclinical Models.

Weidle U, Birzele F Cancer Genomics Proteomics. 2025; 22(2):136-165.

PMID: 39993805 PMC: 11880926. DOI: 10.21873/cgp.20494.

Candidate Genetic Loci Modifying the Colorectal Cancer Risk Caused by Lifestyle Risk Factors.

Barot S, Vermani L, Blom J, Larsson S, Liljegren A, Lindblom A Clin Transl Gastroenterol. 2024; 16(1):e00790.

PMID: 39665592 PMC: 11756881. DOI: 10.14309/ctg.0000000000000790.

HDAC-driven mechanisms in anticancer resistance: epigenetics and beyond.

Minisini M, Mascaro M, Brancolini C Cancer Drug Resist. 2024; 7:46.

PMID: 39624079 PMC: 11609180. DOI: 10.20517/cdr.2024.103.

Tasquinimod promotes the sensitivity of ovarian cancer cells to cisplatin by down-regulating the HDAC4/p21 pathway.

Li Z, Wu Y, Guo Y, Min X, Lin Y Korean J Physiol Pharmacol. 2024; 29(2):191-204.

PMID: 39539173 PMC: 11842298. DOI: 10.4196/kjpp.24.132.

Development of Novel ROCK Inhibitors via 3D-QSAR and Molecular Docking Studies: A Framework for Multi-Target Drug Design.

Beljkas M, Petkovic M, Vuletic A, Djuric A, Santibanez J, Srdic-Rajic T Pharmaceutics. 2024; 16(10).

PMID: 39458584 PMC: 11514586. DOI: 10.3390/pharmaceutics16101250.

References

Franklin K, Shields C, Haynes K . Beyond the marks: reader-effectors as drivers of epigenetics and chromatin engineering. Trends Biochem Sci. 2022; 47(5):417-432. PMC: 9074927. DOI: 10.1016/j.tibs.2022.03.002. View

Zhang L, Sun Y, Fei M, Tan C, Wu J, Zheng J . Disruption of chaperone-mediated autophagy-dependent degradation of MEF2A by oxidative stress-induced lysosome destabilization. Autophagy. 2014; 10(6):1015-35. PMC: 4091166. DOI: 10.4161/auto.28477. View

Lee B, Kim Y, Kim H, Kim D, Won H, Kim Y . HDAC4 degradation by combined TRAIL and valproic acid treatment induces apoptotic cell death of TRAIL-resistant head and neck cancer cells. Sci Rep. 2018; 8(1):12520. PMC: 6104079. DOI: 10.1038/s41598-018-31039-8. View

Zang W, Hu Y, Qian C, Feng Y, Liu J, Yang J . HDAC4 promotes the growth and metastasis of gastric cancer via autophagic degradation of MEKK3. Br J Cancer. 2022; 127(2):237-248. PMC: 9296555. DOI: 10.1038/s41416-022-01805-7. View

Xu D, Gao Y, Hu N, Wu L, Chen Q . miR-365 Ameliorates Dexamethasone-Induced Suppression of Osteogenesis in MC3T3-E1 Cells by Targeting HDAC4. Int J Mol Sci. 2017; 18(5). PMC: 5454890. DOI: 10.3390/ijms18050977. View

Brancolini C, Iuliano L . Proteotoxic Stress and Cell Death in Cancer Cells. Cancers (Basel). 2020; 12(9). PMC: 7563887. DOI: 10.3390/cancers12092385. View

Bousset L, Gil J . Targeting senescence as an anticancer therapy. Mol Oncol. 2022; 16(21):3855-3880. PMC: 9627790. DOI: 10.1002/1878-0261.13312. View

Han X, Niu J, Zhao Y, Kong Q, Tong T, Han L . HDAC4 stabilizes SIRT1 via sumoylation SIRT1 to delay cellular senescence. Clin Exp Pharmacol Physiol. 2015; 43(1):41-6. DOI: 10.1111/1440-1681.12496. View

Pablo Tortola C, Fielitz B, Li Y, Rudebusch J, Luft F, Fielitz J . Activation of Tripartite Motif Containing 63 Expression by Transcription Factor EB and Transcription Factor Binding to Immunoglobulin Heavy Chain Enhancer 3 Is Regulated by Protein Kinase D and Class IIa Histone Deacetylases. Front Physiol. 2021; 11:550506. PMC: 7838639. DOI: 10.3389/fphys.2020.550506. View

10.

Jiang H, Jia D, Zhang B, Yang W, Dong Z, Sun X . Exercise improves cardiac function and glucose metabolism in mice with experimental myocardial infarction through inhibiting HDAC4 and upregulating GLUT1 expression. Basic Res Cardiol. 2020; 115(3):28. DOI: 10.1007/s00395-020-0787-1. View

11.

Klempner S, Fabrizio D, Bane S, Reinhart M, Peoples T, Ali S . Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. Oncologist. 2019; 25(1):e147-e159. PMC: 6964127. DOI: 10.1634/theoncologist.2019-0244. View

12.

Mathias R, Guise A, Cristea I . Post-translational modifications regulate class IIa histone deacetylase (HDAC) function in health and disease. Mol Cell Proteomics. 2015; 14(3):456-70. PMC: 4349969. DOI: 10.1074/mcp.O114.046565. View

13.

Yang Q, Tang J, Xu C, Zhao H, Zhou Y, Wang Y . Histone deacetylase 4 inhibits NF-κB activation by facilitating IκBα sumoylation. J Mol Cell Biol. 2020; 12(12):933-945. PMC: 7948076. DOI: 10.1093/jmcb/mjaa043. View

14.

Jebessa Z, Shanmukha K, Dewenter M, Lehmann L, Xu C, Schreiter F . The lipid droplet-associated protein ABHD5 protects the heart through proteolysis of HDAC4. Nat Metab. 2019; 1(11):1157-1167. PMC: 6861130. DOI: 10.1038/s42255-019-0138-4. View

15.

Zhang Y, Ren Y, Guo L, Ji C, Hu J, Zhang H . Nucleus accumbens-associated protein-1 promotes glycolysis and survival of hypoxic tumor cells via the HDAC4-HIF-1α axis. Oncogene. 2017; 36(29):4171-4181. PMC: 5537617. DOI: 10.1038/onc.2017.51. View

16.

Lahm A, Paolini C, Pallaoro M, Nardi M, Jones P, Neddermann P . Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci U S A. 2007; 104(44):17335-40. PMC: 2077257. DOI: 10.1073/pnas.0706487104. View

17.

Zhou L, Zheng S, Rosas Bringas F, Bakker B, Simon J, Bakker P . A synthetic lethal screen identifies HDAC4 as a potential target in MELK overexpressing cancers. G3 (Bethesda). 2021; 11(12). PMC: 8664443. DOI: 10.1093/g3journal/jkab335. View

18.

Kuznetsov J, Aguero T, Owens D, Kurtenbach S, Field M, Durante M . BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers. Sci Adv. 2019; 5(9):eaax1738. PMC: 6750916. DOI: 10.1126/sciadv.aax1738. View

19.

Su L, Luo Y, Yang Z, Yang J, Yao C, Cheng F . MEF2D Transduces Microenvironment Stimuli to ZEB1 to Promote Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer. Cancer Res. 2016; 76(17):5054-67. DOI: 10.1158/0008-5472.CAN-16-0246. View

20.

Chen S, Sang N . Hypoxia-Inducible Factor-1: A Critical Player in the Survival Strategy of Stressed Cells. J Cell Biochem. 2015; 117(2):267-78. PMC: 4715696. DOI: 10.1002/jcb.25283. View